Fulcrum Therapeutics (FULC) Cash from Investing Activities (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Cash from Investing Activities for 7 consecutive years, with -$1.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Investing Activities fell 146.42% to -$1.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.7 million through Dec 2025, down 4.69% year-over-year, with the annual reading at $30.7 million for FY2025, 4.69% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$1.0 million at Fulcrum Therapeutics, down from $18.6 million in the prior quarter.
  • The five-year high for Cash from Investing Activities was $38.1 million in Q1 2024, with the low at -$106.6 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$4.5 million, with a median of $3.3 million recorded in 2024.
  • The sharpest move saw Cash from Investing Activities crashed 11561.06% in 2021, then soared 934.58% in 2023.
  • Over 5 years, Cash from Investing Activities stood at -$9.1 million in 2021, then crashed by 299.85% to -$36.4 million in 2022, then surged by 150.48% to $18.4 million in 2023, then crashed by 87.69% to $2.3 million in 2024, then crashed by 146.42% to -$1.0 million in 2025.
  • According to Business Quant data, Cash from Investing Activities over the past three periods came in at -$1.0 million, $18.6 million, and $13.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.